Long-Term Safety and Effectiveness of Adalimumab in Japanese Patients with Noninfectious Intermediate, Posterior, or Panuveitis: Post-Marketing Surveillance of 251 Patients

被引：0
|
作者：
Kenichi Namba
Toshikatsu Kaburaki
Hidekazu Tsuruga
Yohei Ogawa
Eri Iwashita
Hiroshi Goto
机构：
[1] Hokkaido University,Department of Ophthalmology, Faculty of Medicine and Graduate School of Medicine
[2] University of Tokyo School of Medicine,Department of Ophthalmology
[3] Jichi Medical University Saitama Medical Center,Department of Ophthalmology
[4] AbbVie GK,Department of Ophthalmology
[5] Tokyo Medical University,undefined
来源：
Ophthalmology and Therapy | 2022年 / 11卷
关键词：
Adalimumab; Behçet’s Disease; Sarcoidosis; Uveitis; Vogt-Koyanagi-Harada Disease;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1147 / 1161
页数：14
相关论文
共 50 条
  • [31] Post-marketing surveillance study of the safety of dexamethasone intravitreal implant in patients with retinal vein occlusion or noninfectious posterior segment uveitis
    Tufail, Adnan
    Lightman, Sue
    Kamal, Ahmed
    Pleyer, Uwe
    Gajate Paniagua, Nuria Maria
    Dots, Corrine
    Li, Xiao-Yan
    Jiao, Jenny
    Lou, Jean
    Hashad, Yehia
    CLINICAL OPHTHALMOLOGY, 2018, 12 : 2519 - 2534
  • [32] EFFICACY AND SAFETY OF PIROZADIL IN LONG-TERM ADMINISTRATION - A STUDY OF POST-MARKETING SURVEILLANCE
    TAPOUNET, R
    MEDICINA CLINICA, 1987, 89 (20): : 858 - 860
  • [33] Long-term safety and effectiveness of linagliptin by baseline body mass index in Japanese patients with type 2 diabetes: a 3-year post-marketing surveillance study
    Yabe, Daisuke
    Yamamoto, Fumiko
    Lund, Soren S.
    Okamura, Tomoo
    Kadowaki, Takashi
    EXPERT OPINION ON DRUG SAFETY, 2022, 21 (10) : 1303 - 1313
  • [34] Long-term safety and effectiveness of linagliptin as add-on therapy in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance
    Ito, Tomohiro
    Naito, Yusuke
    Shimmoto, Naoki
    Ochiai, Kaori
    Hayashi, Naoyuki
    Okamura, Tomoo
    EXPERT OPINION ON DRUG SAFETY, 2021, 20 (03) : 363 - 371
  • [35] Long-term safety and effectiveness of eculizumab in patients with AQP4+neuromyelitis optica spectrum disorder: 3 years of data from Japanese post-marketing surveillance
    Nakahara, Jin
    Nakashima, Ichiro
    Yokote, Hiroaki
    Manabe, Yasuhiro
    Okamura, Kazumi
    Hasegawa, Kou
    Fujihara, Kazuo
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 144 - 144
  • [36] Long-term safety and effectiveness of biosimilar insulin glargine in Japanese patients with diabetes mellitus in routine clinical practice: results of a post-marketing safety study
    Shingaki, Tomotaka
    Taki, Kentaro
    Koyanagi, Momoha
    Nagaoka, Soshi
    Yoshizawa, Kenichi
    Oki, Norika
    Yoshikawa, Aki
    Imaoka, Takeshi
    CURRENT MEDICAL RESEARCH AND OPINION, 2020, 36 (06) : 947 - 958
  • [37] Safety and effectiveness of clofarabine in Japanese patients with relapsed/refractory acute lymphoblastic leukaemia: a post-marketing surveillance study
    Kazama, Hirotaka
    Nishina, Satoshi
    Seto, Takeshi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024, 54 (07) : 778 - 786
  • [38] Safety and effectiveness of secukinumab subcutaneous injection in Japanese patients with psoriasis vulgaris and psoriatic arthritis: A post-marketing surveillance
    Fujishige, Ayako
    Seko, Noriko
    JOURNAL OF DERMATOLOGY, 2025, 52 (01): : 11 - 23
  • [39] Safety and Effectiveness of Molnupiravir in Japanese Patients with COVID-19: Final Report of Post-marketing Surveillance in Japan
    Shinozaki, Shohei
    Watanabe, Asuka
    Kimata, Masahiro
    Miyazaki, Makoto
    Maekawa, Shinichiroh
    INFECTIOUS DISEASES AND THERAPY, 2024, 13 (01) : 189 - 205
  • [40] Safety and effectiveness of denosumab in Japanese patients with rheumatoid arthritis: A 2-year post-marketing surveillance study
    Tanaka, Yoshiya
    Mizutani, Hideki
    Fujii, Kunimitsu
    Okubo, Naoki
    MODERN RHEUMATOLOGY, 2023, 34 (05) : 927 - 935
12345